Q2: $502 million
Full Year: $2.04 billion
Earnings per Share
Full Year: $11.58
•Because of uncertainty surrounding system sales in
the United States, Intuitive Surgical hasn’t been
•That being said, how the company performs against
expectations will go a long way in determining the
stock’s fate over the short-term.
•It will be interesting to see if management feels
comfortable reinstating guidance moving forward.
Many investors will
be watching to see
if U.S. hospitals will
start loosening the
purse strings to buy
•For years, the company showed double digit growth in
system sales for the daVinci in the United States. That
growth actually went negative earlier this year.
•Investors shouldn’t read too much into the system sales
themselves, as uncertainty surrounding the Affordable
Care Act is still lingering, and hospitals are likely
wanting to see if the new daVinci Xi is worth the money.
•Instead, focus on management comments regarding
reception to the Xi.
In order to be
for decades to come,
the daVinci needs to
help doctors perform
surgery in ever-more
•Historically, the company’s machine has been most oft-
used to perform hysterectomies and prostatectomies.
•Last year, however, leading voices in the women’s
health industry questioned the efficacy of using the
daVinci to perform hysterectomies.
•Some believe the new Xi will help diversify the types of
procedures the daVinci can be used for. Listen in for
specific results in “general surgery”, and comments by
Smart investors know dividend stocks like Abbott
Labs crush their non-dividend paying counterparts
over the long term. Our top analysts put together a
report on a group of high-yielding stocks that
should be in any income investor’s portfolio.